Exercise stress testing: Time to restart in nuclear cardiology?

[No abstract available

A second wave of COVID-19 infections should not lead to a new disruption of services in nuclear cardiology

[No abstract available

COVID-19 and nuclear cardiology: Introducing the “forward” virtual visit

[No abstract available

Premature CAD: Conventional Screening and Diagnostic Strategies May Not Capture the “Whole Picture”

[No abstract available

Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA

Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can “carry” the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa). © 2018 Taylor & Francis Group, LLC